Navigation Links
MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
Date:1/31/2008

e new 600 mg arm. Results from the study are expected to be reported in the third calendar quarter 2008.

Jim DeMesa, M.D., President and CEO of MIGENIX added, "With results from this study expected in the third quarter 2008, we now have another near-term clinical milestone. Additional key clinical milestones include Omigard Phase III results for preventing catheter-related infections (CLIRS study) expected by our partner, Cadence Pharmaceuticals, in the second half of 2008 (enrollment to be completed in the second quarter) and Cutanea Life Sciences, our partner in the CLS001 rosecea product, planning to advance CLS001 to Phase III."

About Celgosivir (MX-3253)

Celgosivir, an oral inhibitor of alpha-glucosidase I, is currently the only anti-HCV drug in clinical development which acts on host-directed glycosylation. In preclinical studies, celgosivir has shown in vitro synergy with various interferons on the market or in development including Pegasys, PEG-Intron, Infergen, Alferon and IFN-omega (with or without ribavirin) and other drugs in development for the treatment of HCV (e.g. polymerase inhibitors) and therefore could have the potential to be included as part of many combination therapeutic approaches to improve efficacy in future anti-HCV therapies.

Results announced in April 2007 from a Phase II study demonstrated a clinically significant benefit when celgosivir was added to the standard of care in non-responder patients. Interim results from the first 10 patients in the current viral kinetics study who had completed 4-weeks of therapy were reported in December 2007. Detailed analysis of data from these two studies, and an extension protocol designed to provide expanded access to the non-responder patients, provided the rationale for increasing the dose of celgosivir from 400mg per day to 600mg per day in combination therapy as the next step for the optimization and advancement of celgosivir.

About HCV

HCV, the most co
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
2. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
3. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
5. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
6. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
7. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
8. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
9. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
10. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
11. Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... According to Jeff Howell, Partner of Nidea ... new development in Downtown Toronto is expanding at a ... 755 storeys of new development last week (including three ... dominating the Toronto skyline for the foreseeable future in ... for new development. , As the Toronto city council ...
(Date:9/15/2014)... phase transitionsthink solid, liquid, and gasbut much ... drops. If phase transitions occur at the ... subtle fluctuations can dramatically transform a material. ... of Energy,s Brookhaven National Laboratory and Stony ... of absolute zero to isolate and probe ...
(Date:9/15/2014)... 16, 2014 Cancer Immunotherapy ... Adoptive T-cell Therapies is a new market research ... the three principal types of therapeutics that have ... in cancer immunotherapy (which is often called "immuno-oncology") ... and Adoptive cellular immunotherapy. , The regular ...
(Date:9/15/2014)... Calif. , Sept. 15, 2014  FlexTech ... (RFP) for flexible, printed product demonstrators (demos) and ... two-stage RFP process with pre-proposals due on October ... 2015.  Funds for proposals ultimately selected are provided ... have a significant cost share by the proposing ...
Breaking Biology Technology:ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Elusive quantum transformations found near absolute zero 2Elusive quantum transformations found near absolute zero 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2
... Thermo Fisher,Scientific Inc. (NYSE: TMO ) announced ... president and chief executive,officer, are adopting stock- trading ... covering the future sale of company stock. Mr.,Dekkers, ... over August,15-17, 2007, has adopted a plan for ...
... Pharmion - ... - Sirtuins implicated in tumor ... combination epigenetic therapies, BOULDER, Colo. and MONTREAL, Aug. 20 ... MYG) today announced a,research collaboration for the development of novel ...
... CLAREMONT, Calif., Aug. 14 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group ... second quarter of 2007 increased more than,35% over the ... times,revenues of just $13,351 for the same period in ... of 2007 were $3,256,000 compared to only,$24,374 in the ...
Cached Biology Technology:Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs 2Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 2Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 3Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 4Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 5Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 6Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 2Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 4Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 5Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 6
(Date:9/16/2014)... us sick can take up residence in and on ... other troublesome symptom, according to new research at Washington ... On average, healthy individuals carry about five types of ... BioMed Central Biology . The study is the ... in healthy people. , The research was conducted ...
(Date:9/16/2014)... dinosaurs 66 million years ago decimated the evergreens among ... their deciduous peers, according to a study led by ... PLOS Biology . , Applying biomechanical formulas ... of angiosperms flowering plants excluding conifers ... a diverse plant community thriving during a 2.2 million-year ...
(Date:9/16/2014)... fall marks a new school year, a new football ... Space Station. In September, SpaceX,s Dragon spacecraft is scheduled ... and investigations as part of the company,s fourth contracted ... will be the third suite of research investigations sponsored ... Space (CASIS). With the role of managing the U.S. ...
Breaking Biology News(10 mins):Healthy humans make nice homes for viruses 2Healthy humans make nice homes for viruses 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3
... sexy (especially when scientists start analyzing it), but it is ... an egg and a sperm, a whole lot of cell ... that carries a mix of genes from both parents. There ... the most fundamental and important is the transition from unfertilized ...
... new drug has been shown to improve blood flow in ... heart attacks, a Monash University study published today reveals. , ... that, in conjunction with Bayer Health Care, hopes to use ... of heart disease. , Dr. Harald Schmidt, Director of the ...
... men age 40 and older have a significantly increased ... whose fathers are younger than 30 years, according to ... General Psychiatry, one of the JAMA/Archives journals. , Autism ... patterns of behavior, according to background information in the ...
Cached Biology News:Cracking the egg 2Heart smart: new drug improves blood flow 2Older fathers more likely to have autistic children 2
Extra Large bottle for hybridization 300 x 70mm...
CQCS kit for first KR 4i , (first unit)....
... compatible with hood installations. ... system for 384-well plates, ... prepares large quantities of ... Wellpro also performs plate ...
...
Biology Products: